

Neuropeptide Y (human, rat, mouse) (TFA)

| | |
|-----------------------------|---|
| Cat. No.: | HY-P0198A |
| Molecular Formula: | C ₁₉₁ H ₂₈₆ F ₃ N ₅₅ O ₅₉ S |
| Molecular Weight: | 4385.7 |
| Sequence: | Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH ₂ <small>YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH₂ (TFA salt)</small> |
| Sequence Shortening: | YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH ₂ |
| Target: | Neuropeptide Y Receptor |
| Pathway: | GPCR/G Protein; Neuronal Signaling |
| Storage: | Sealed storage, away from moisture and light, under nitrogen Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen) |

SOLVENT & SOLUBILITY

| | | | | | | |
|---|--|--------------------------|------|-----------|-----------|-----------|
| In Vitro | H ₂ O : 100 mg/mL (22.80 mM); Need ultrasonic) | | | | | |
| | | Solvent Concentration | Mass | 1 mg | 5 mg | 10 mg |
| | Preparing Stock Solutions | 1 mM | | 0.2280 mL | 1.1401 mL | 2.2801 mL |
| | | 5 mM | | 0.0456 mL | 0.2280 mL | 0.4560 mL |
| | | 10 mM | | 0.0228 mL | 0.1140 mL | 0.2280 mL |
| Please refer to the solubility information to select the appropriate solvent. | | | | | | |
| In Vivo | 1. Add each solvent one by one: PBS Solubility: 100 mg/mL (22.80 mM); Clear solution; Need ultrasonic | | | | | |

BIOLOGICAL ACTIVITY

| | |
|--------------------|--|
| Description | Neuropeptide Y (human) TFA is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β -Amyloid toxicity. |
| In Vitro | It is showed that Neuropeptide Y (human) is able to protect cortical neurons from A β ₂₅₋₃₅ toxicity. 2 μ M NPY abolishes the toxic effects of A β ₂₅₋₃₅ at 24 and 48 h. The same effect on neuronal survival is observed in neurons exposed to 1 μ M and 0.5 μ M Neuropeptide Y (human) pretreatments. Pretreatment with Neuropeptide Y (29-64), amide, human (TFA) Increases NGF Synthesis, reduces NGF mRNA, and restores NGF release in cortical neurons exposed to A β ₃₅₋₂₅ ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

PROTOCOL

Cell Assay ^[1]

Primary cortical neurons are preincubated either alone (positive control) or with three concentrations of Neuropeptide Y (human) (NPY) (0.5, 1, and 2 μ M) for 24 h and then exposed to A β ₂₅₋₃₅ (50 μ M) or A β ₃₅₋₂₅ (50 μ M) for 48 h^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Croce N, et al. Neuropeptide Y protects rat cortical neurons against β -amyloid toxicity and re-establishes synthesis and release of nerve growth factor. ACS Chem Neurosci. 2012 Apr 18;3(4):312-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA